Pharmacokinetics of gentamicin C1, C1a and C2 in horses after single intravenous dose.

The research article analyzes the behavior and movement (pharmacokinetics) of the different components of an antibiotic called gentamicin (C1, C1a, C2) in horses, when given a single intravenous dose. The study revealed notable differences in how these three components are eliminated from the body, as well as their half-life and stay duration within the body, which could have impacts on their medicinal and potential side effects.

Research Methodology

• The study focused on analyzing pharmacokinetics – the branch of pharmacology dealing with the movement of drugs in the body – of gentamicin components C1, C1a, and C2 in horses.
• The researchers administered a total volume of gentamicin at 6.6 mg/kg bodyweight to 6 healthy mature horses and observed the clearance, half-life (t 1/2), and mean residence time (MRT) – the average time a molecule stays within the body – of each component.

Results of the Study

• Significant differences were observed between the pharmacokinetic behavior of gentamicin C1a and the other two components (C1 and C2).
• The total body clearance (the rate at which a drug is eliminated from the body) of gentamicin C1a was found to be 1.62 +/- 0.50 ml/min x kg, a rate similar to the glomerular filtration rate (GFR) – the rate of blood flow through the kidneys – reported for horses.
• The clearance rate of the other components, gentamicin C1 and C2, was slower (1.03 +/- 0.08 ml/min x kg and 1.10 +/- 0.15 ml/min x kg, respectively).
• The apparent volume of distribution at steady states – a measurement of how a drug spreads out in the body – for gentamicin C1, C1a and C2 were 0.22 +/- 0.05, 0.26 +/- 0.12 and 0.23 +/- 0.05 l/kg respectively.
• The mean residence time (MRT) and half-life (t 1/2) calculations for gentamicin C1a were significantly shorter than those of gentamicin C1 and C2.

Implications of the Study

• The differences in pharmacokinetics among the gentamicin components can have potential pharmacological and toxicological implications. For example, these differences could affect how effective the drug is and the severity of any side effects.
• Understanding these differences might help in better managing drug dosage and reach optimal drug delivery in the treatment process, especially in horses.
• The results can also contribute to establishing dosage recommendations and understanding potential side effects of gentamicin use in horses and possibly other veterinary applications.